Stratrix
On the Record · Mylan II B.V.

Mylan II B.V. acquisitions, on the record

The businesses Mylan II B.V. bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
non-sterile, topicals-focused business (the "Topicals Business") of Renaissance Acquisition Holdings, LLC ("Renaissance")
Word for word“Our most recent significant acquisitions include the June 2016 acquisition of the non-sterile, topicals-focused business (the “Topicals Business”) of Renaissance Acquisition Holdings, LLC (“Renaissance”) for approximately $1.01 billion in cash at closing, including amounts that were deposited into escrow for potential contingent payments.” 10-K for 2017
acquisitionJune 2016approximately $1.01 billion in cash at closing
Meda AB (publ.) ("Meda")
Word for word“Also, in August 2016, we acquired Meda AB (publ.) (“Meda”) for a total purchase price of approximately $6.92 billion , net of cash acquired.” 10-K for 2017
acquisitionAugust 2016approximately $6.92 billion , net of cash acquired
Matrix Laboratories Limited
Word for word“Acquisitions, including that of Matrix Laboratories Limited (2007); Merck KGaA’s generics and specialty pharmaceutical business (2007); the EPD Business (as defined below) (2015) and Meda AB (publ.) (“Meda”) (2016), have played a significant role in our transformation.” 10-K for 2018
acquisition2007—
Merck KGaA’s generics and specialty pharmaceutical business
Word for word“Acquisitions, including that of Matrix Laboratories Limited (2007); Merck KGaA’s generics and specialty pharmaceutical business (2007); the EPD Business (as defined below) (2015) and Meda AB (publ.) (“Meda”) (2016), have played a significant role in our transformation.” 10-K for 2018
acquisition2007—
Abbott Laboratories’ non-U.S. developed markets specialty and branded generics (“Bx”) business (the “EPD Business”)
Word for word“Mylan became a public limited liability company in the Netherlands through its acquisition of Abbott Laboratories’ non-U.S. developed markets specialty and branded generics (“Bx”) business (the “EPD Business”) on February 27, 2015.” 10-K for 2018
acquisitionFebruary 27, 2015—
the non-sterile, topicals-focused business (the “Topicals Business”) of Renaissance Acquisition Holdings, LLC
Word for word“Contributing to the overall increase in total revenues were the incremental net sales from the acquisitions of Meda and the non-sterile, topicals-focused business (the “Topicals Business”) of Renaissance Acquisition Holdings, LLC of approximately $1.41 billion .” 10-K for 2018
acquisition—approximately $1.41 billion
Apicore
Word for word“cash paid for acquisitions, net totaling approximately $65.9 million related to the deferred non-contingent purchase price for the acquisition of Apicore;” 10-K for 2018
acquisition—approximately $65.9 million
Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business (the EPD Business)
Word for word“Mylan became a public limited liability company in the Netherlands through its acquisition of Abbott Laboratories’ non-U.S. developed markets specialty and branded generics (“Bx”) business (the “EPD Business”) on February 27, 2015.” 10-K for 2019
acquisitionFebruary 27, 2015—
As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Cash received from selling businessesGoodwill from acquisitions
2016-12-31$6.48 billion$0$4 billion
2017-12-31$167 million$86.7 million$92.2 million
2018-12-31$65.9 million$29.3 million—
2019-12-31$148.7 million$28 million—

Deal filings since 2016

Read from Mylan II B.V.’s annual reports (10-K for 2019, 10-K for 2018, 10-K for 2017) and the financial data it files with the SEC, as of 2020-02-28. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.